Research Analysts’ Weekly Ratings Changes for GH Research (GHRS)

GH Research (NASDAQ: GHRS) recently received a number of ratings updates from brokerages and research firms:

• 8/8/2026 – GH Research was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/7/2026 – GH Research had its price target raised by Guggenheim from $34.00 to $40.00. They now have a “buy” rating on the stock.
• 8/7/2026 – GH Research had its price target raised by Cantor Fitzgerald from $35.00 to $40.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – GH Research had its price target raised by Needham & Company LLC from $32.00 to $39.00. They now have a “buy” rating on the stock.
• 7/27/2026 – GH Research is now covered by Wells Fargo & Company. They set an “overweight” rating and a $44.00 price target on the stock.
• 7/27/2026 – GH Research is now covered by Wells Fargo & Company. They set an “overweight” rating and a $44.00 price target on the stock.
• 7/17/2026 – GH Research had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – GH Research was downgraded by Zacks Research from “hold” to “strong sell”.

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.